The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer
Purpose. Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide. Hormonal deprivation therapy is a well-established treatment for locally advanced or metastatic diseases but exposes patients to the risk of osteoporosis and fragility fractures. Furthermore, the tropism o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2018/1525832 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561264337879040 |
|---|---|
| author | Diomidis Kozyrakis Dionyssios Paridis Stefanos Perikleous Konstantinos Malizos Anastasios Zarkadas Antonios Tsagkalis |
| author_facet | Diomidis Kozyrakis Dionyssios Paridis Stefanos Perikleous Konstantinos Malizos Anastasios Zarkadas Antonios Tsagkalis |
| author_sort | Diomidis Kozyrakis |
| collection | DOAJ |
| description | Purpose. Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide. Hormonal deprivation therapy is a well-established treatment for locally advanced or metastatic diseases but exposes patients to the risk of osteoporosis and fragility fractures. Furthermore, the tropism of the PCa cells to osseous metastases increases the incidence of skeletal-related events (SREs). Methods. A nonsystematic review of the international literature was performed in respect to the use of osteoclast inhibitors zoledronic acid (ZA) and denosumab (DEN) in PCa patients. Results. DEN and ZA have proved their efficacy in preventing osteoporosis and bone mass loss in patients treated with hormonal therapy with no proven superiority of one agent over the other. However, the effectiveness in reducing fragility fractures has been proved only for DEN so far. In metastatic-free castrate-sensitive high-risk PCa patients, ZA has not shown any efficacy in preventing osseous metastasis, and evidence is lacking in favor or against the use of DEN. The use of osteoclasts inhibitors had no evident positive effect in overall and disease-specific survival in this group of patients. In advanced castrate-refractory malignancy, DEN has shown clinical superiority over ZA in preventing new SRE but not in overall survival. Conclusion. Superiority of DEN over ZA has been proved only in advanced castrate refractory disease in terms of preventing new SRE. In the rest of the cases, the selection of either agent should be based on the clinical condition of each patient and the cost of the treatment. |
| format | Article |
| id | doaj-art-0661e03012594c10b4f4fb82fbae1440 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-0661e03012594c10b4f4fb82fbae14402025-02-03T01:25:22ZengWileyAdvances in Urology1687-63691687-63772018-01-01201810.1155/2018/15258321525832The Current Role of Osteoclast Inhibitors in Patients with Prostate CancerDiomidis Kozyrakis0Dionyssios Paridis1Stefanos Perikleous2Konstantinos Malizos3Anastasios Zarkadas4Antonios Tsagkalis5Department of Urology, “Achillopouleio” General Hospital of Volos, Magnesia, GreeceDepartment of Orthopaedics, Animus-Kyanous Hospital, Larisa, GreeceDepartment of Urology, “Achillopouleio” General Hospital of Volos, Magnesia, GreeceDepartment of Orthopaedics, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, GreeceDepartment of Urology, “Achillopouleio” General Hospital of Volos, Magnesia, GreeceDepartment of Orthopaedics, Animus-Kyanous Hospital, Larisa, GreecePurpose. Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide. Hormonal deprivation therapy is a well-established treatment for locally advanced or metastatic diseases but exposes patients to the risk of osteoporosis and fragility fractures. Furthermore, the tropism of the PCa cells to osseous metastases increases the incidence of skeletal-related events (SREs). Methods. A nonsystematic review of the international literature was performed in respect to the use of osteoclast inhibitors zoledronic acid (ZA) and denosumab (DEN) in PCa patients. Results. DEN and ZA have proved their efficacy in preventing osteoporosis and bone mass loss in patients treated with hormonal therapy with no proven superiority of one agent over the other. However, the effectiveness in reducing fragility fractures has been proved only for DEN so far. In metastatic-free castrate-sensitive high-risk PCa patients, ZA has not shown any efficacy in preventing osseous metastasis, and evidence is lacking in favor or against the use of DEN. The use of osteoclasts inhibitors had no evident positive effect in overall and disease-specific survival in this group of patients. In advanced castrate-refractory malignancy, DEN has shown clinical superiority over ZA in preventing new SRE but not in overall survival. Conclusion. Superiority of DEN over ZA has been proved only in advanced castrate refractory disease in terms of preventing new SRE. In the rest of the cases, the selection of either agent should be based on the clinical condition of each patient and the cost of the treatment.http://dx.doi.org/10.1155/2018/1525832 |
| spellingShingle | Diomidis Kozyrakis Dionyssios Paridis Stefanos Perikleous Konstantinos Malizos Anastasios Zarkadas Antonios Tsagkalis The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer Advances in Urology |
| title | The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer |
| title_full | The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer |
| title_fullStr | The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer |
| title_full_unstemmed | The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer |
| title_short | The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer |
| title_sort | current role of osteoclast inhibitors in patients with prostate cancer |
| url | http://dx.doi.org/10.1155/2018/1525832 |
| work_keys_str_mv | AT diomidiskozyrakis thecurrentroleofosteoclastinhibitorsinpatientswithprostatecancer AT dionyssiosparidis thecurrentroleofosteoclastinhibitorsinpatientswithprostatecancer AT stefanosperikleous thecurrentroleofosteoclastinhibitorsinpatientswithprostatecancer AT konstantinosmalizos thecurrentroleofosteoclastinhibitorsinpatientswithprostatecancer AT anastasioszarkadas thecurrentroleofosteoclastinhibitorsinpatientswithprostatecancer AT antoniostsagkalis thecurrentroleofosteoclastinhibitorsinpatientswithprostatecancer AT diomidiskozyrakis currentroleofosteoclastinhibitorsinpatientswithprostatecancer AT dionyssiosparidis currentroleofosteoclastinhibitorsinpatientswithprostatecancer AT stefanosperikleous currentroleofosteoclastinhibitorsinpatientswithprostatecancer AT konstantinosmalizos currentroleofosteoclastinhibitorsinpatientswithprostatecancer AT anastasioszarkadas currentroleofosteoclastinhibitorsinpatientswithprostatecancer AT antoniostsagkalis currentroleofosteoclastinhibitorsinpatientswithprostatecancer |